Skip to main content

Loading market data...

INCY

Incyte Corporation

NASDAQ • United states

$115.15

-$1.46

(-1.26%)

Source: Yahoo Finance · Quote time Oct 21, 2026 14:48 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Incyte Corporation (INCY)

Unavailable

Quotes may be delayed

$23.34B

Market Cap

182,261

Volume

16.3

P/E Ratio

Unavailable

Div Yield

Incyte Corporation Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

1 Sep 2026

Incyte Corporation reported Another company event

Incyte Corporation filed an 8-K covering another company event.

29 Jul 2026

Incyte Corporation filed Form 10-Q

Incyte Corporation submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

28 Jul 2026

Incyte Corporation reported Operating or financial results

Incyte Corporation filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

7 Jul 2026

Incyte Corporation reported Another company event

Incyte Corporation filed an 8-K covering another company event, supporting financial statements or exhibits.

22 Jun 2026

Incyte Corporation reported Another company event

Incyte Corporation filed an 8-K covering another company event.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$3.46B

Total assets (USD)$7.34B

Total liabilities (USD)$1.72B

Shareholders' equity (USD)$5.62B

Long-term debt (USD)$19.09B

Debt due within a year (USD)$689.12M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 31 Mar 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q1 2026	$1.27B	$301.12M	$303.33M	$1.47	10-Q · 28 Apr 2026
Q4 2025	$1.51B	$335.86M	$299.33M	Unavailable	10-K · 10 Feb 2026
Q3 2025	$1.37B	$443.52M	$424.17M	$2.11	10-Q · 28 Oct 2025
Q2 2025	$1.22B	$530.31M	$405.00M	$2.04	10-Q · 29 Jul 2025
Q1 2025	$1.05B	$205.17M	$158.20M	$0.80	10-Q · 29 Apr 2025
Q4 2024	$1.18B	$301.51M	$201.20M	Unavailable	10-K · 10 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $131.80

14.5% upside potential

📈

Strong Buy

Unavailable

👍

Buy

11

⏸️

Hold

10

📉

Sell

0

21 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 14:48 UTC Targets range 104.00–157.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

15

Oct 2026

CAGNONI PABLO J

President, Global Head of R&D

Option exercise

$65.76 per share

2,642 shares

15

Oct 2026

CAGNONI PABLO J

President, Global Head of R&D

Open-market sale

$112.71 per share

2,642 shares

1

Oct 2026

Heeson Lee

EVP, Head of Incyte Intl

Tax withholding

$117.14 per share

463 shares

30

Sep 2026

BAKER BROS. ADVISORS LP

Director

Grant or award

Unavailable per share

644 shares

30

Sep 2026

Clancy Paul J

Director

Grant or award

$121.35 per share

203 shares

30

Sep 2026

HARRIGAN EDMUND

Director

Grant or award

$121.35 per share

206 shares

22

Sep 2026

Gardner David H

EVP, Chief Strategy Officer

Tax withholding

$126.93 per share

920 shares

15

Sep 2026

CAGNONI PABLO J

President, Global Head of R&D

Option exercise

$66.39 per share

23,218 shares

15

Sep 2026

CAGNONI PABLO J

President, Global Head of R&D

Open-market sale

$120.49 per share

23,218 shares

25

Aug 2026

Basi Ramitpal K

EVP, Human Resources

Tax withholding

$129.72 per share

504 shares

Top Shareholders

Baker Bros. Advisors Lp

30,762,330 shares

0.058% change

6/30/2026

Vanguard Group Inc

19,911,434 shares

-0.201% change

12/31/2025

Blackrock, Inc.

18,032,718 shares

-4.982% change

6/30/2026

Dodge & Cox

11,957,326 shares

-2.408% change

6/30/2026

Vanguard Capital Management Llc

11,024,289 shares

0.862% change

6/30/2026

State Street Corp

9,722,336 shares

0.84% change

6/30/2026

Vanguard Portfolio Management Llc

7,791,091 shares

0.411% change

6/30/2026

Aqr Capital Management Llc

5,320,901 shares

-8.386% change

6/30/2026

Geode Capital Management, Llc

4,750,735 shares

1.011% change

6/30/2026

Lsv Asset Management

4,123,759 shares

5.196% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 14:48 UTC· 15 hours ago

Research coverage and investment tools

Incyte Corporation (INCY) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch). Its last price was US$115.15 on 21 Oct 2026. That is 64% of the way from its 52-week low of US$84.02 to its 52-week high of US$132.60. Its market capitalisation was US$23.34 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q1 2026	$1.27B	$301.12M	$303.33M	$1.47	—	23.7%	—	10-Q · 28 Apr 2026 (opens in a new tab)
Q4 2025	$1.51B	$335.86M	$299.33M	Unavailable	—	22.3%	—	10-K · 10 Feb 2026 (opens in a new tab)
Q3 2025	$1.37B	$443.52M	$424.17M	$2.11	—	32.5%	—	10-Q · 28 Oct 2025 (opens in a new tab)
Q2 2025	$1.22B	$530.31M	$405.00M	$2.04	—	43.6%	—	10-Q · 29 Jul 2025 (opens in a new tab)
Q1 2025	$1.05B	$205.17M	$158.20M	$0.80	—	19.5%	—	10-Q · 29 Apr 2025 (opens in a new tab)
Q4 2024	$1.18B	$301.51M	$201.20M	Unavailable	—	25.6%	—	10-K · 10 Feb 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/28/2026	$2.80	$1.76	+59.1%
Mar 2026	4/28/2026	$1.55	$1.14	+36.0%
Dec 2025	2/10/2026	$1.56	$1.64	-4.9%
Sep 2025	10/28/2025	$2.03	$1.38	+47.1%

Cash and equivalents: $3.46B
Total assets: $7.34B
Total liabilities: $1.72B
Shareholders' equity: $5.62B
Long-term debt: $19.09B
Debt due within a year: $689.12M

8-K · 1 Sep 2026

Incyte Corporation reported Another company event (opens in a new tab)

Incyte Corporation filed an 8-K covering another company event.
10-Q · 29 Jul 2026

Incyte Corporation filed Form 10-Q (opens in a new tab)

Incyte Corporation submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 28 Jul 2026

Incyte Corporation reported Operating or financial results (opens in a new tab)

Incyte Corporation filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 7 Jul 2026

Incyte Corporation reported Another company event (opens in a new tab)

Incyte Corporation filed an 8-K covering another company event, supporting financial statements or exhibits.
8-K · 22 Jun 2026

Incyte Corporation reported Another company event (opens in a new tab)

Incyte Corporation filed an 8-K covering another company event.

Insider	Date	Transaction	Shares	Average price	Filing
CAGNONI PABLO J President, Global Head of R&D	15 Oct 2026	Option exercise (M)	+2,642	$65.76	Form 4 (opens in a new tab)
CAGNONI PABLO J President, Global Head of R&D	15 Oct 2026	Open-market sale (S)	−2,642	$112.71	Form 4 (opens in a new tab)
Heeson Lee EVP, Head of Incyte Intl	1 Oct 2026	Tax withholding (F)	−463	$117.14	Form 4 (opens in a new tab)
BAKER BROS. ADVISORS LP Director	30 Sep 2026	Grant or award (A)	+644	—	Form 4 (opens in a new tab)
Clancy Paul J Director	30 Sep 2026	Grant or award (A)	+203	$121.35	Form 4 (opens in a new tab)
HARRIGAN EDMUND Director	30 Sep 2026	Grant or award (A)	+206	$121.35	Form 4 (opens in a new tab)
Gardner David H EVP, Chief Strategy Officer	22 Sep 2026	Tax withholding (F)	−920	$126.93	Form 4 (opens in a new tab)
CAGNONI PABLO J President, Global Head of R&D	15 Sep 2026	Option exercise (M)	+23,218	$66.39	Form 4 (opens in a new tab)
CAGNONI PABLO J President, Global Head of R&D	15 Sep 2026	Open-market sale (S)	−23,218	$120.49	Form 4 (opens in a new tab)
Basi Ramitpal K EVP, Human Resources	25 Aug 2026	Tax withholding (F)	−504	$129.72	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Baker Bros. Advisors Lp	6/30/2026	30,762,330	0.058%
Vanguard Group Inc	12/31/2025	19,911,434	-0.201%
Blackrock, Inc.	6/30/2026	18,032,718	-4.982%
Dodge & Cox	6/30/2026	11,957,326	-2.408%
Vanguard Capital Management Llc	6/30/2026	11,024,289	0.862%
State Street Corp	6/30/2026	9,722,336	0.84%
Vanguard Portfolio Management Llc	6/30/2026	7,791,091	0.411%
Aqr Capital Management Llc	6/30/2026	5,320,901	-8.386%
Geode Capital Management, Llc	6/30/2026	4,750,735	1.011%
Lsv Asset Management	6/30/2026	4,123,759	5.196%

Previous close: 116.62 USD
Day range: 115.13 – 116.57 USD
52-week range: 84.02 – 132.60 USD
Volume: 182,261
Market cap: $23.34B
Average volume: 1,475,130
P/E ratio: 16.3
EPS (FY 2025, diluted): 6.41 USD
Shares outstanding: 202.70M
Beta (5Y monthly): 0.78

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 14:48 UTC· 15 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:18 UTC· 15 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for INCY yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.